GLP-1 News
Latest articles and news about GLP-1 on AXL Media.
Latest Articles
- Large Cohort Study Links GLP-1 Receptor Agonists to Modest Risk Increase for Rare Optic Neuropathy
Published: May 1, 2026
Section: Medical News
A significant medical study has identified a correlation between the use of GLP-1 receptor agonists and a heightened risk of developing nonarteritic anterior ischemic optic neuropa...
- Indiana University Researchers Identify Weight-Loss Mechanism That Eliminates Need for GLP-1 Hormones
Published: May 1, 2026
Section: Medical News
Preclinical research published in Molecular Metabolism reveals that combining glucagon and GIP hormone activities can achieve significant weight loss without the gastrointestinal s...
- Experimental Five-Target Molecule Outperforms Semaglutide in Correcting Obesity and Diabetes in Preclinical Trials
Published: May 1, 2026
Section: Health Technology
Researchers have developed a single-molecule "quintuple agonist" that combines incretin-based signaling with the insulin-sensitizing properties of lanifibranor to treat metabolic d...
- Why GLP-1 Medications Fail for 20% of Users: Research Suggests Combination Therapy as a Potential Solution
Published: May 1, 2026
Section: Fitness & Exercise
While GLP-1 receptor agonists like Wegovy and Zepbound have revolutionized weight management, a significant subset of users—as many as one in five—experience suboptimal results. Ne...
- New Clinical Guidelines Advise Nurse Practitioners on Expanding GLP-1 Receptor Agonist Indications and Risks
Published: Apr 28, 2026
Section: Medical News
A comprehensive review published in The Nurse Practitioner details the evolving role of GLP-1 receptor agonists beyond diabetes management into cardiovascular and renal protection....
- Experimental Endoscopic Gut Reset Procedure Shows Potential to Prevent Weight Regain After GLP-1 Cessation
Published: Apr 24, 2026
Section: Medical News
A new study presented at Digestive Disease Week 2026 indicates that duodenal mucosal resurfacing (DMR) may prevent the weight rebound commonly seen after stopping GLP-1 medications...
- New Research Reveals Sharp Social Stigma and "Effort Bias" Against Patients Using GLP-1 Weight Loss Drugs
Published: Apr 24, 2026
Section: Mental Health
A multi-national study published in Scientific Reports indicates that individuals who use anti-obesity medications are judged as having less moral character and being less deservin...
- Endoscopic Duodenal Resurfacing Offers Breakthrough for Sustaining Weight Loss After Discontinuing GLP-1 Medications
Published: Apr 23, 2026
Section: Medical News
A randomized, sham-controlled trial presented at Digestive Disease Week 2026 suggests that duodenal mucosal resurfacing (DMR) significantly mitigates weight regain following the ce...
- A Potential Catalyst in Eli Lilly’s 150-Year History
Published: Apr 18, 2026
Section: Companies & Industry
Eli Lilly, a titan in the pharmaceutical industry for a century and a half, is navigating a pivotal moment with the recent launch of Foundayo, an oral GLP-1 treatment. The company,...
- GLP-1 Weight Loss Study Reveals Higher Social Stigma and "Shortcut" Biases Against White Women
Published: Apr 18, 2026
Section: Mental Health
A new study from Georgetown University finds that women using GLP-1 medications for weight loss face significantly harsher social judgment than those using traditional diet and exe...
- AI Analysis of 400,000 Reddit Posts Identifies Unreported Side Effects Linked to Popular GLP-1 Weight-Loss Drugs
Published: Apr 10, 2026
Section: Medical News
University of Pennsylvania researchers utilized large language models to scan over half a decade of social media discussions regarding semaglutide and tirzepatide. The study uncove...
- Amazon Pharmacy Integrates Eli Lilly’s Foundayo Weight-Loss Pill into Same-Day Kiosk Network
Published: Apr 10, 2026
Section: Science & Tech
Amazon.com announced on Thursday that its pharmacy division will stock Eli Lilly’s newly approved oral weight-loss medication, Foundayo, at automated kiosks and offer same-day deli...